Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Teijin Aims for Sales of \120 Bil.
June 26, 2006
- Takeda Ties-Up with Cephalon
June 26, 2006
- JPMA
June 26, 2006
- Mediceo Paltac to Acquire
June 26, 2006
- NEW PRODUCTS
June 26, 2006
- Lilly Initiates PIII Study
June 26, 2006
- Amended PAL Will Create New Business
June 26, 2006
- HMW Fucoidan Inhibits
June 26, 2006
- Healthcare Reform-related Bill Passes the Diet
June 26, 2006
- 8th Meeting of JSCPS
June 26, 2006
- New Drug Data Protection
June 26, 2006
- R&D NEWS IN BRIEF
June 26, 2006
- SURVEY 4 articles
June 19, 2006
- SELF-MEDICATION NEWS IN BRIEF
June 19, 2006
- Abilify to Accelerate Otsuka's
June 19, 2006
- MIYARISAN Licenses
June 19, 2006
- Diet Approves PAL Amendment
June 19, 2006
- Respiratory Drugs to Be
June 19, 2006
- NHI Price Listing Announced for
June 19, 2006
- BUSINESS NEWS IN BRIEF
June 19, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…